FY2025 EPS Estimates for Alector Raised by Cantor Fitzgerald

Alector, Inc. (NASDAQ:ALEC) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Alector in a report issued on Thursday, February 27th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($2.02) for the year, up from their previous forecast of ($2.55). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.88) per share.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.59. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%. The business had revenue of $54.24 million during the quarter, compared to analyst estimates of $20.41 million.

A number of other research analysts have also issued reports on the company. Mizuho lowered Alector from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $2.50 in a report on Tuesday, December 17th. BTIG Research decreased their target price on Alector from $16.00 to $5.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Morgan Stanley lowered Alector from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $10.00 to $3.00 in a report on Tuesday, November 26th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Alector in a report on Thursday. Finally, Stifel Nicolaus lowered Alector from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.75.

Alector Stock Down 1.2 %

ALEC opened at $1.64 on Monday. Alector has a 52 week low of $1.55 and a 52 week high of $7.57. The business has a fifty day simple moving average of $1.77 and a 200-day simple moving average of $3.50. The firm has a market cap of $162.50 million, a P/E ratio of -0.96 and a beta of 0.61.

Institutional Trading of Alector

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC increased its position in shares of Alector by 1.0% during the third quarter. FMR LLC now owns 14,595,014 shares of the company’s stock worth $68,013,000 after purchasing an additional 137,794 shares in the last quarter. RA Capital Management L.P. acquired a new position in Alector in the 4th quarter valued at about $18,324,000. JPMorgan Chase & Co. increased its position in Alector by 64.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock valued at $12,716,000 after acquiring an additional 1,072,298 shares during the period. Geode Capital Management LLC increased its position in Alector by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company’s stock valued at $3,619,000 after acquiring an additional 10,308 shares during the period. Finally, Deerfield Management Company L.P. Series C increased its position in Alector by 1.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,066,962 shares of the company’s stock worth $2,017,000 after purchasing an additional 11,770 shares during the period. Institutional investors and hedge funds own 85.83% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.